Karboplatin etkileşimleri

Aminoglycosides : Avoid concomitant use with aminoglycosides. (Karboplatin etiketi, İlaç etkileşimleri)

…hydroxide, magnesium hydroxide Prevention or Management: Phenytoin and antacids should not be taken at the same time of day Antineoplastic agents (usually in combination) Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam,… (Fenitoin etiketi, İlaç etkileşimleri)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (Karboplatin etiketi, İlaç etkileşimleri)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (Karboplatin etiketi, İlaç etkileşimleri)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (Karboplatin etiketi, İlaç etkileşimleri)

• NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (Sorafenib etiketi, Kontrendikasyonlar)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (Karboplatin etiketi, İlaç etkileşimleri)

…methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam,… (Fosfenitoin etiketi, İlaç etkileşimleri)

…patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly protein-bound paclitaxel for Injectable Suspension (albumin-bound) and every-3-week carboplatin after ANC recovers to at least 1,500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an ANC of at least 500 cells/mm 3 and platelet count of… (Paklitaksel etiketi, Uyarılar ve önlemler)

In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (Trastuzumab etiketi, Uyarılar ve önlemler)

Effects of VEGZELMA on Other Drugs No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38, interferon alfa, carboplatin or paclitaxel was observed when bevacizumab was administered in combination with these drugs; however, 3 of the 8 patients receiving bevacizumab with paclitaxel and carboplatin had lower paclitaxel… (Bevasizumab etiketi, İlaç etkileşimleri)